National Drug Policy 2015 2020 Aug15
National Drug Policy 2015 2020 Aug15
National Drug Policy 2015 2020 Aug15
2015 to 2020
Minimise alcohol and other drug-related harm and
promote and protect health and wellbeing
Citation: Inter-Agency Committee on Drugs. 2015.
National Drug Policy 2015 to 2020. Wellington: Ministry of Health.
Compassion is crucial. Help needs to be available for those who need it, interventions need to happen early, and
the stigma that acts as a barrier to help seeking and recovery needs to be reduced. This National Drug Policy
emphasises the need for a people-centred intervention system that is responsive to people’s circumstances,
environment and life stages.
We also have to be prepared to challenge traditional approaches and ways of thinking about these issues.
Innovation is essential in a world where new drugs are detected every week and the black market has gone
digital. The international landscape has also shifted, with a growing recognition that the harms we are trying to
prevent can come from our approach to drugs as much as from their use.
Different drugs have different risk profiles and our responses to them need to reflect this. In some cases, such as
with methamphetamine, we want to eradicate all supply and use. For alcohol, we want those who choose to drink
to do so moderately and those who are pregnant or planning pregnancy not to drink at all. When legislating to try
and reduce harmful behaviour we need to ensure the rules and penalties we implement are both proportionate to
the potential for harm and evidence-based.
In relation to alcohol, the Government has already responded by tightening the rules on the sale of alcohol and
putting more control in the hands of local communities through the Sale and Supply of Alcohol Act 2012,
reducing the blood-alcohol limit for driving and increasing alcohol screening and brief interventions in primary
care.
Actions are also included in this National Drug Policy as the Government’s response to the Law Commission’s
recommendations on the Misuse of Drugs Act 1975. These relate to ensuring the Expert Advisory Committee on
Drugs has appropriate decision-making guidance, ensuring appropriate access to controlled drugs for medical
purposes (while minimising the risk of diversion), and assessing options for possession and utensils offences to
incorporate an enhanced health response.
New Zealand continues to make strong progress in minimising alcohol and other drug harm. Hazardous
consumption of alcohol has decreased over the last six years from 18 percent in 2006/07 to 16 percent in
2013/14. The Prime Minister’s Methamphetamine Action Plan has helped to more than halve the reported rates
of amphetamine use. The combined focus on restricting the supply of methamphetamine and its precursors, with
treatment and community-based initiatives has contributed to this reduction.
There is still, however, a lot to do. The Government has set a range of Better Public Services targets and other
social sector initiatives to make New Zealand a better place to live for all New Zealanders. These targets and
initiatives include reducing long-term welfare dependence, supporting vulnerable children, boosting skills and
employment, and reducing crime. When we dig beneath the surface of many of the issues we need to address to
achieve these outcomes, we find that misuse of alcohol and drugs is a contributing factor.
There is no quick fix. Progress will take time, and will require coordinated action across the social sector and
other agencies to understand where to target resources and provide wrap-around support. Partnership with non-
governmental organisations, businesses, communities and families will also be vital in minimising alcohol and
other drug related harm. As Minister responsible for this Government’s policy on alcohol and other drugs, I will
Introduction 1
New Zealand has high rates of alcohol and other drug use 1
Misuse of AOD harms individuals, communities and society 2
Taking action to minimise harm means looking at the whole picture 2
An investment-based approach ensures support goes where it will make the biggest difference 3
A collaborative response to AOD harm is needed 3
The Government is committed to getting results 4
Our objectives 9
Delaying the uptake of AOD by young people 9
Reducing illness and injury from AOD 11
Reducing hazardous drinking of alcohol 13
Shifting our attitudes towards AOD 15
Our strategies 17
References 27
Further resources 30
New Zealand has high rates of alcohol and other drug use
Over a lifetime 44 percent of New Zealanders will have tried an illegal drug and 93 percent will have drunk
alcohol (Ministry of Health 2015b). A number of adults aged 15+ use illegal drugs:
® 1 in 13 smoke cannabis at least once a month (Ministry of Health 2015b)2
® 1 in 37 have used ecstasy in the last year(Ministry of Health 2015b)
® 1 in 100 have used amphetamine in the last year (Ministry of Health 2014c).
Some people are psychologically or physiologically dependent on these substances. This means they have
become so used to having AOD in their system they need to keep using them in order to function normally. It is
estimated that 12 percent of the population will experience a substance use disorder at some stage in their lives
(Wells et al 2007).
Additionally, a recent study found that approximately 11 percent of New Zealand secondary school students use
substances at a level that are likely to cause them significant current harm and may cause long-term problems
(The University of Auckland 2014).
For example, approximately 4500 people receiving a health-related benefit have a primary diagnosis of alcohol
or substance abuse and a quarter of these people have received a benefit for at least 10 years.
1
Other drugs include: substances classified under the Medicines Act 1981 or Misuse of Drugs Act 1975 and not used within the controls set out in legislation
or for their intended purpose; substances captured by the Psychoactive Substances Act 2013; and other substances such as solvents and aerosols.
2
Data for cannabis and ecstasy use in the last 12 months (as at 2012/13) are provisional and potentially subject to revision or change until they have been
through the full quality assurance process and received final approval for release.
Harmful impacts of AOD are not restricted to the individual using the substance. Examples of AOD-related
harm to others include violence, foetal AOD exposure, family break-up and child neglect, property crime and
public health issues such as the spread of hepatitis.
Problematic AOD use is often multi-generational and can be normalised within family and whānau groups. Such
patterns of behaviour may also normalise actions that will bring people, particularly young people, into contact
with the criminal justice system, such as cannabis offences or drink driving.
Particular populations often experience a disproportionate amount of harm. For this Policy to be successful,
harm needs to be minimised for all populations.
The complexity of these issues means that our responses need to be flexible, targeting the needs of different
populations, family and whānau situations and environments, and responding to emerging issues early.
Approaches need to be evaluated, tested and refined using domestic and international evidence and best practice.
New Zealand is not alone in facing the challenge of reducing harm caused by AOD. We can learn from
international practice, policy and structures. This includes international agreements, such as the United Nations
Drug Conventions, trade agreements and human rights instruments. The Government will monitor innovative
approaches as they are tested internationally, including experimental regimes that make cannabis available for
medicinal use.
By focusing on prevention and early intervention at the population level, through to targeted, people-centred
responses for those individuals who need greater support, we can reduce these harms and their flow on effects to
families, whānau, communities and the wider public. The Policy’s first Priority Area for action is targeted
specifically at ensuring a people-centred intervention system.
Government agencies have a role by collaborating, supporting and partnering with others to achieve common
goals. In particular, the principles of partnership, participation and protection will continue to underpin the
relationship between government and Māori to achieve pae ora3 and health equity by supporting the health and
wellbeing aspirations of Māori.
The IACD will report to the Government annually. Their advice will cover progress on implementing actions,
whether objectives are being achieved, and any changes to actions and timelines that may be required as
evidence emerges. The IACD will also provide advice on whether achieving the objectives of this Policy is
helping to drive progress on the government’s broader social sector goals, including the Better Public Services
Result Areas.
3
Pae ora is a holistic concept including three interconnected elements of mauri ora (healthy individuals), whanau ora (healthy families) and wai ora (healthy
environments). Pae ora is also the Government’s vision for Māori health and can be accessed through http://www.health.govt.nz/our-work/populations/
maori-health/he-korowai-oranga/pae-ora-healthy-futures.
Making progress towards this goal will impact on wider social objectives, and in particular four of the Better
Public Services Result Areas in relation to reducing welfare dependency, supporting vulnerable children,
boosting skills and employment and reducing crime.
Progress on these objectives will mean progress on reducing overall harm from AOD. To know whether progress
is being made, high-level indicators and measures have been developed. These will be based on the latest
available data and will enable high-level trends to be assessed.
The approach is similar to that used in other countries, including the United Kingdom, Australia and many
nations in the European Union.
Problem limitation aims to reduce harm that is already occurring to those who use AOD or those
affected by someone else’s AOD use. It includes activities that provide safer equipment and
environments for AOD use, ensure access to quality AOD treatment services through New
Zealand’s health system, and support people in recovery. It also includes activities that support
others who are affected, such as the children of people with dependence problems.
Demand reduction aims to reduce the desire to use AOD. It includes activities that delay or
prevent uptake. This means reducing use through education, health promotion, advertising and
marketing restrictions, and influencing the conditions that make people turn to AOD through
community action, such as keeping children in school.
Supply control aims to prevent or reduce the availability of AOD. It includes controlling New
Zealand’s borders to prevent illegal drugs being imported, and shutting down domestic growing,
manufacturing and supply. It also aims to control and manage the supply of legal drugs through
things like prescribing guidelines, age restrictions, licensing conditions and permitted trading
hours.
Each priority area has an initial set of actions to be undertaken by 2017/18. These actions are drawn from across
the three strategies and build on, rather than replace, the significant contributions government, communities and
individuals already make to the goal and objectives of this Policy.
Many of the initial actions are designed to enhance collaboration and links across government, service providers
and communities in order to achieve better outcomes collectively than can be achieved alone. This collaborative
approach recognises that everyone has a role in minimising AOD-related harm, but that the Government has a
responsibility to lead.
The initial actions are also designed to build a foundation to better enable individuals, families and communities
to contribute to the Policy’s goals and objectives, and to support prevention and intervention activity, particularly
for young people.
By age 15 one in four people have drunk alcohol and one in six have used an
illegal drug (Ministry of Health 2015a and 2015b).
Early use of AOD raises very serious issues for our children and society. The brain does not fully mature until
the third decade of life, and the evidence suggests that exposure to AOD during adolescence and young
adulthood may interrupt important neurological processes and natural brain maturation. This can have
consequences for social and neurobiological functioning in adulthood (Squeglia et al 2009; Office of the Prime
Minister’s Science Committee and Gluckman 2011). This is more likely when people start using AOD earlier
(early onset) and do so regularly or heavily.
Early onset of alcohol consumption tends to increase the likelihood of regular and heavy use and has been
associated with increased rates of violence and injury, unprotected sex, mental health problems, suicide, poorer
educational outcomes and problem drinking later in life (Dawson et al 2008; Fergusson et al 1994; Hingston et al
2006, 2009; Komro et al 2010; Office of the Prime Minister’s Science Advisory Committee 2011; Swahn et al
2010). Of adults aged 15 years and over who reported drinking hazardously in the past 12 months 48 percent had
first used alcohol before age 15 (Ministry of Health 2015b).
The evidence highlights that early onset of cannabis use also tends to increase the likelihood of
misuse, as well as mental health issues, other illicit drug use, school drop-out and educational
underachievement, neurocognitive deficits and injury (Meier et al 2012; Office of the Prime
Minister’s Science Advisory Committee 2011; Silins et al 2014).
The way that we respond to young people’s use of AOD can have life-long consequences. Accordingly, the
Prime Minister’s Chief Science Advisor warns against responding punitively to behaviours that reflect
incomplete maturation (Office of the Prime Minister’s Chief Science Advisor 2011). Drugs (excluding alcohol)
were the second most prevalent reason cited by school boards for exclusions4 in 2013, accounting for 17 percent,
and the main reason for expulsions,5 at 34 percent (Ministry of Education 2013). Not being able to participate
fully in school life can limit a young person’s ability to gain employment, sustain relationships and make life
choices. Similarly, consequences from interaction with the criminal justice system from low-level AOD-related
offending can be far reaching. During 2013/14 (ie, fiscal year ending 30 June 2014) 2410 police proceedings 6 for
illicit drug possession or use against youth (aged 5–24) were recorded, with approximately a quarter resulting in
court action.7
AOD use accounts for about 5 percent of all health loss9 experienced by New
Zealanders and 23 percent of mental illness, mainly through substance use
4
Exclusion means the formal removal of a student aged under 16 from the school and the requirement that the student enrol elsewhere.
5
Expulsion means the formal removal of a student aged 16 or over from the school. If the student wishes to continue schooling, he or she may enrol
elsewhere.
6
Proceedings include court action, formal and informal warnings, non-court referred conferences and other non-court action.
7
These figures have been produced from a statistical dataset that is still under development, and which will, in the future be used to produce Recorded Crime
Offender Statistics. Those Tier 1 statistics should be available from 1 July 2015.
8
Data for other drug use in the last 12 months (as at 2012/13) are provisional and potentially subject to revision or change until they have been through the
full quality assurance process and received final approval for release.
9
Health loss is a measure of how much healthy life is lost due to early death, illness or disability.
Sharing needles and other drug utensils remains the key route for hepatitis C
virus transmission in New Zealand. Eighty-three percent of people with hepatitis
C virus infection report a history of intravenous drug use (Gane et al 2014).
AOD taken recreationally produces physiological changes to the body. These effects are generally intended to be
pleasurable, but they also have the potential to cause considerable harm to the people that use them and to others.
Each year about 150,000 New Zealanders aged 16 and older experience substance use problems that could
benefit from an intervention (Mental Health Commission 2011). Different drugs also carry different risk profiles
and the impact on individuals will vary depending on their vulnerabilities, environmental and social
circumstances and patterns of use.
Around 800 deaths per year are attributable to alcohol. Injuries are the dominant cause of alcohol-attributable
deaths for people under 45, with alcohol-induced cancers becoming increasingly dominant from the age of 45
(Connor et al 2013). Alcohol-attributable injuries are estimated to account for 11 percent of all ACC claims, at a
cost of $350 million per year (Accident Compensation Corporation 2012).
Regular and heavy cannabis smokers are at increased risk of contracting chronic bronchitis,
respiratory infections and pneumonia when compared to non-smokers and may suffer cancers
of the lung (Room et al 2008).
Rates of accidental poisonings (including overdose) are higher for opioids such as heroin, methadone and
codeine than for any other illegal drug in New Zealand. These substances are also the most likely to be injected,
which can cause vein damage and increase exposure to communicable diseases. Availability of clean equipment
will reduce harm: the introduction of the 1-for-1 needle exchange has reduced the rate of hepatitis C infection
among people who currently inject drugs by around 25 percent (Noller and Henderson 2014; Henderson et al
2011).
Additionally, stopping use of alcohol or other drugs after daily or frequent use over a couple of months can
trigger withdrawal symptoms. Most people will experience mild to moderate symptoms, but for some, the effects
will be more serious (for example, alcohol and benzodiazepine withdrawal can be fatal (Bayard et al 2004; Lann
and Molina 2009)).
Relapse is common, and people who have stopped using even for a short period of time are at risk of over-dosing
should they resume use. Relapse prevention plans and transition plans between services – for example from
specialist care to primary care – are important tools to assist people with recovery.
One in three 18–24-year-olds drink at levels that are hazardous to their health
(Ministry of Health 2014b).
It is encouraging that both total and hazardous consumption of alcohol by New Zealanders aged 15+ has reduced
over the last six years (Ministry of Health 2014b).
® The proportion of the adult population who drink has decreased from 84 percent in 2006/07 to 80 percent in
2013/14.
® The proportion who drink hazardously has decreased from 18 percent in 2006/07 to 16 percent in 2013/14.
Despite these positive trends, the rates of hazardous drinking continue to be high. Approximately 575,000 New
Zealanders report drinking in a way that carries a risk of harm to themselves and others around them.
Additionally, while total and hazardous consumption of alcohol by young people aged 18–24 also decreased
between 2006/07 and 2013/14 (from 89 to 84 percent and 43 to 33 percent respectively) this group remains most
likely to drink hazardously (Ministry of Health 2014b).
Hazardous drinking can contribute to a number of social harms – not just to individuals, but
also to those around them. The most common harmful effects reported by adults due to
someone else’s drinking are damage to friendships and social life, and damage to home life and
financial position (Ministry of Health 2010). Alcohol consumption is also a factor in offending
behaviour. Police estimate that at least one-third of recorded violent offences and 15 percent of
sexual offences occur after the offender has consumed alcohol (New Zealand Police 2009).
Babies exposed to alcohol before birth can develop lifelong problems, including behavioural problems,
intellectual disability and heart defects. This can lead to poor life outcomes and increased risk of involvement
with the criminal justice and welfare systems. There is no cure for Fetal Alcohol Spectrum Disorders (FASD),
but they are preventable. For women who are pregnant or planning a pregnancy, the safest option is to avoid
drinking alcohol.
New Zealand has relatively high rates of alcohol consumption during pregnancy, with up to a third of New
Zealand women consuming some alcohol while pregnant, and around 10 percent drinking heavily (Morton et al
2010; Mallard et al 2013; Ministry of Health 2015a). The Health Select Committee’s Inquiry into Improving
Child Health Outcomes and Preventing Child Abuse, with a Focus from Pre-conception until Three years of Age
identified estimates of the number of babies born each year in New Zealand with FASD ranging from 173 to
3000.
There is also evidence that parental alcohol use can harm children. Children with parents or caregivers who drink
heavily are likely to suffer from a greater number of hospital admissions for physical injuries (Families
Commission 2006). Children raised by caregivers who are alcohol dependent can have higher levels of anxiety,
behavioural problems and other mental health issues than children who do not have alcohol-dependent parents
(Maynard 1997). Research also suggests that children of alcohol-dependent parents are more likely to become
alcohol dependent themselves, creating generational impacts (Jennison and Johnson 1998).
10
Ministry of Health, 2014b. The Alcohol Use Disorders Identification Test (AUDIT) developed by the World Health Organization is used to identify
hazardous drinking patterns. The AUDIT is a 10-item questionnaire covering alcohol consumption, alcohol-related problems, and abnormal drinking
behaviour. Each question is scored from 0 to 4, so the questionnaire has a maximum score of 40. An AUDIT score of 8 or more is defined as hazardous
drinking.
Measure Hazardous drinking score (AUDIT) in past-year drinkers aged 15 years and
over
Data source New Zealand Health Survey (annual)
2011/12 Baseline: 19%
Measure Women who had been pregnant in the last 12 months and drank during most
recent pregnancy
Data source New Zealand Health Survey (5 yearly)
2012/13 Baseline: 19%
Twenty-five percent of high school age students thought it was okay for people
their age to drink alcohol, and 10 percent thought it was okay to use cannabis
(almost the same number as for cigarettes) (Adolescent Health Research Group
2013).
Around 50,000 people wanted help to reduce their AOD use in the past 12
months but had, for a variety of reasons, not received it (Mental Health
Commission 2011).
Our attitudes are a key predictor of our behaviour. They are shaped by our individual values and beliefs, the
values and beliefs of our peers and people of influence, and by our surroundings, such as the messages we are
exposed to and the rules set by the Government.
People use AOD for many reasons, including enjoyment of the effects, relaxation, alleviation of stress or a
depressed mood, to enhance an activity, to better bond with peers, and to keep awake at night to socialise (Boys
et al 2001; Duff 2008; Jay 1999). Young people have also reported that they have used drugs to ‘fit in’ with
peers, to cope with problems, to relieve boredom, and to rebel (Ministry of Health 2009b).
In most cases AOD use is not problematic. For example, many people enjoy moderate
consumption of alcohol in social settings with few ill effects. However, harm can result when
people misuse AOD, particularly when social patterns of misuse and intoxication become
entrenched.
There are many reasons why people who feel they need help for their AOD use might not seek assistance to do
so. These include not being ready to stop use, not knowing where to go for help or encountering long waiting
lists, and being concerned about the potential negative effects on employment, or that receiving help might cause
others to have a negative opinion of them (Ministry of Health 2009b). For example, a dedicated
methamphetamine telephone helpline service found that many callers were deeply concerned about
confidentiality because of such fears. Information that allowed them to self-manage their issues was often
considered more important than seeing a counsellor. Offering people a variety of choices for treatment is more
likely to change behaviour than limiting support to only a few options. Several studies have found that substance
use disorders are more highly stigmatised than other health conditions (Livingston et al 2012).
Stigma can also impact people’s recovery journey. For many people, recovery means assuming some control
over their lives. This means being able to be better parents, to be employed, and to live as others do. This can be
difficult if they encounter discrimination for their past actions. As well as their AOD use, their offending
histories can severely limit future possibilities, for example, cannabis convictions can limit someone’s ability to
travel overseas, or to get a job.
Over the medium to long term, achieving our objectives will require shifting the attitudes of individuals and
communities to AOD use and misuse, and to seeking help. But, as we have seen with tobacco and drink-driving,
it is possible to shift attitudes over time.
Measure Adults aged 15+ who sought or have been given advice, information or help
on how to cut back their drinking in the last 12 months 11
Data source HPA Alcohol Behaviours and Attitudes Survey (annual)
Baseline 2013: 5%
11
Note that this question is only asked of people who had consumed two or more drinks on their last drinking occasion (within the last three months).
Problem limitation
Barriers are removed to people accessing and receiving support or treatment for their own or others’
AOD use
New Zealand is working in this area to:
® provide effective, high-quality, compassionate, timely, accessible, and age- and culture-appropriate support
and treatment services
® address the factors that have an impact on people’s ability to access treatment and support, including
destigmatising help-seeking
® provide AOD services that are responsive to people with co-existing problems
® ensure all frontline services (justice, health, education, etc) provide an entry point to AOD support, referral
and treatment (including for the child affected by a parent’s addiction)
® support and strengthen harm reduction approaches such as the needle exchange programme
® ensure continuity of care for people transitioning from one service or environment to another, including
from youth to adult services, and between justice facilities and the community.
Demand reduction
People have the knowledge, skill and support to make good decisions about their AOD use
New Zealand is working in this area to:
® ensure messages about AOD harm, harm reduction and help- seeking (including information about less
harmful consumption and means of administration) are consistent, evidence-based, accessible and
relevant
® tailor messages, resources and services appropriately to respond to different cultures, populations and
communities
® encourage women to abstain from AOD use (or use less harmful substitutions, such as methadone, where
appropriate) during pregnancy and while breast feeding
® bring about a societal shift in attitudes about harmful AOD use.
Often they work well together, but sometimes they come into conflict and require a balancing act. For example,
fear of the legal consequences of using an illegal drug can act as a barrier to some people seeking the help they
need. In these instances, assessment of the best available evidence is needed to determine which mix of
approaches is required to best address social, economic and health harms. This is harm minimisation in action.
This Policy makes a commitment to an initial set of actions, and these will be reviewed and updated by the end
of 2017. The actions are drawn from across the three strategies and will build on, rather than replace, the
significant contributions that government, communities and individuals already make to the goal and objectives
of this Policy.
The AOD landscape continues to evolve, and new evidence will continue to emerge about the issues that need to
be addressed and the effectiveness of the interventions aimed at addressing them. The IACD will review the
progress made and emerging evidence, and will provide advice on a revised set of actions in 2017. This will
ensure initiatives are added, cancelled and amended as appropriate, to reflect changes in AOD issues and
evidence on the effectiveness of interventions.
The Prime Minister’s Youth Mental Health Project introduced national waiting time targets for 12–19 year olds
to be seen within three weeks of contacting a youth alcohol and drug service and with eight weeks of referral
from a service. Initial results show that youth are being provided with better access to timely and appropriate
treatment and follow-up (Ministry of Health 2014). However, we need to continue to monitor this to avoid
access slipping.
All many people may need is reliable, internet-based information, or their family doctor or school nurse asking
about their drinking and drug-taking habits and providing advice. For children of parents with addiction issues, it
could be that a specific plan is required to ensure their needs are looked after.
These actions will integrate closely with the Government’s Rising to the Challenge plan for mental health and
addiction services, and the new ways of working to target government services and provide wrap-around
responses through the Government’s Better Public Services Result Areas.
If we are going to achieve real change, then, just like smoking, AOD misuse needs to become less desirable and
help-seeking encouraged with the right support available at the right time. Social sector agencies also need to
work together to identify people who need additional support and tailor responses and services to their needs.
This includes young people whose schooling is impacted by AOD use, people not in education or employment,
and people affected by a fetal alcohol spectrum disorder.
Making progress in this area will require sustained effort over a considerable period. Change will be gradual, but
efforts in this area will be vital in the long term.
Communities play an integral role in mobilising and sustaining change, so we will also develop a set of actions
that builds the capacity and capability of communities, particularly those most affected by AOD use and related
harm.
Legislation and law enforcement acts to prevent and deter people from accessing and using AOD harmfully.
Laws set the boundaries of what can be legally sold and under what circumstances and whether penalties enable
health- oriented responses where an offence has been committed.
For example:
® recent changes to the regulation of alcohol and psychoactive substances have set national requirements,
while giving communities a greater say about where and when these products will be sold
® the pilot for the Alcohol and Other Drug Treatment Court offers offenders the opportunity to enter an
intensive treatment programme for their AOD dependency with frequent, random drug testing, and, if their
participation is successful, for this to be taken into account when they are sentenced.
The enforcement of the Misuse of Drugs Act 1975 also provides scope to offer low-level offenders alternatives
to the criminal justice system. For example, a study into cannabis use offences in New Zealand between 1991
and 2008 found a substantial decline in arrests, prosecutions and convictions for cannabis use over that period.
This was despite any changes to the statutory penalties for cannabis use since the enactment of the Misuse of
Drugs Act in 1975 (Wilkins et al 2012).
Evaluate the Alcohol and other Drug Treatment Court Pilot 2017/18
As well as contributing to broader societal harms, certain families and communities are disproportionately
affected by these activities (for example, children living in clandestine laboratories).
Disrupting activity as far up the supply chain as possible is a continuing focus for New Zealand enforcement
agencies. For example, ‘Taskforce GHOST’ – an operation in December 2013 conducted by New Zealand
Police, the Organised and Financial Crime Agency of New Zealand and the New Zealand Customs Service –
prevented 578 kg of pseudoephedrine and 16 kg of ephedrine entering the country and being used in the
domestic methamphetamine manufacturing process.
To successfully disrupt organised crime enforcement efforts must be supported by initiatives aimed at reducing
social harm. These initiatives need to address the social, economic and cultural factors that facilitate the
recruitment of individuals by organised crime groups. We need to place emphasis both on building resilience in
communities with a large organised crime presence and supporting individuals and families to turn away from
the organised crime environment.
Collection, use and sharing of information is vital if we are to anticipate and respond to AOD issues early and
effectively, and target policy, interventions, services and resources where they will have the greatest impact. Making
information accessible is also crucial in order for communities to decide the AOD issues that are important to them
and that shape their environment, and for individuals to be able to make informed choices about their own AOD use.
Develop Tier 1 statistics for alcohol and other drug harm 2015/16
® provide guidance to support schools dealing with AOD issues and helping students who 2016/17
need it, with a focus on keeping students engaged where possible
® develop guidance for improving AOD intervention for services engaging with young people 2016/17
not in education or employment
Priority Area 3 – Getting the legal balance right
® work with the Expert Advisory Committee on Drugs to ensure that harm minimisation is a 2015/16
central feature of drug classification assessments
® review the regulation of controlled drugs for legitimate purposes (such as medicines) 2017/18
alongside reviews of the Medicines Act and other therapeutics legislation
® develop options for further minimising harm in relation to the offence and penalty regime for 2017/18
personal possession within the Misuse of Drugs Act 1975
® release a discussion document seeking feedback on appropriate regulation of drug utensils 2015/16
® introduce the Substance Addiction (Compulsory Assessment and Treatment) Bill to 2015/16
Parliament
® develop a New Zealand position for United Nations General Assembly Special Session on 2015/16
Drugs 2016
® review the effectiveness of new police powers to deal with breaches of local alcohol bans 2015/16
introduced through the Local Government (Alcohol Reform) Amendment Act 2012
® evaluate the Alcohol and other Drug Treatment Court Pilot 2017/18
® commence a review of the policy and operation of the Psychoactive Substances Act 2013 2017/18
Priority Area 4 – Disrupting organised crime
® conduct the National Cannabis and Crime Operation to disrupt the activities of organised Annual
crime groups involved in the cultivation of cannabis
® implement the Whole of Government Action Plan on Tackling Gangs 2017/18
® work with authorities in drug source and transit countries to break precursor chemical and Ongoing
drug supply chains into New Zealand
® continue multi-agency investigations and targeting operations focussed on identified Ongoing
vulnerabilities of key organised crime groups and the supply chain
® implement the Organised Crime and Anti-corruption Legislation Bill provisions 2017/18
Priority Area 5 – Improving information flow
® develop Tier 1 statistics for alcohol and other drug harm 2015/16
® develop a multi-agency Early Warning System to monitor emerging trends and inform 2016/17
enforcement and harm reduction strategies
® update the New Zealand Drug Harm Index 2016/17
® publish a literature review of population level AOD impacts and unmet needs 2015/16
® Adolescent Health Research Group. 2013. The Health and Wellbeing of New Zealand Secondary School Students in
2012: Youth’12 prevalence tables. Auckland: University of Auckland. URL: https://cdn.auckland.ac.nz/assets/fmhs/
faculty/ahrg/docs/ 2012prevalence-tables-report.pdf
® Boys A, Marden J, Strang J. 2001. Understanding reasons for drug use amongst young people: a functional perspective.
Health Education Research 16: 457–69.
® Bayard M, Mcintyre J, Hill K, Woodside J, Quillen J. 2004. Alcohol Withdrawal Syndrome. Am Fam Physician Mar
15; 69(6): 1443–1450.
® Business and Economic Research Limited (BERL). 2009. Costs of Harmful Alcohol and Other Drug Use. Wellington:
BERL Economics.
® Connor J, Kydd R, Shield K, et al. 2013. Alcohol-attributable Burden of Disease and Injury in New Zealand: 2004 and
2007. Wellington: Health Promotion Agency.
® Dawson DA, Goldstein RB, Chou SP, Ruan WJ, Grant BF. 2008. Age at first drink and the first incidence of adult-
onset DSM-IV alcohol use disorders. Alcoholism: Clinical and Experimental Research 32(12): 2149–60.
® Doll R, Peto R, Boreham J, Sutherland I. 2004. Mortality in relation to smoking: 50 years’ observations on male British
doctors. BMJ (Clinical research ed.) 328(7455): 1519.
® Duff C. 2008. Research paper: The pleasure in context. International Journal of Drug Policy
19: 384–392.
® Families Commission. 2006. Families and Heavy Drinking: Impacts on children’s wellbeing: Systematic review. URL:
http://www.superu.govt.nz/sites/default/files/downloads/BS-families-and-heavy- drinking.pdf
® Fergusson DM, Lynskey MT, Horwood LJ. Alcohol consumption and associated problems in a birth cohort of 15 year
olds. New Zealand Medical Journal 1994(107): 167–170.
® Fergusson DM, Lynskey MT, Horwood LJ. 1996. Alcohol misuse and juvenile offending in adolescence. Addiction
91(4): 483–94.
® Gane E, Stedman C, Brunton C, Radke S, Henderson C, Estes C, Razavi H. 2014. Impact of improved treatment on
disease burden of chronic hepatitis C in New Zealand. New Zealand Medical Journal 127(1407): 61–47.
® Gray R, Gordon C, Newcombe R. 2014. Experiences with alcohol consumption culture and environments. [In Fact].
Wellington: Health Promotion Agency Research and Evaluation Unit.
® Henderson C, Brunton C, Lauzon C. 2011. Final Report of the National Needle Exchange Blood-borne Virus
Seroprevalence Survey [BBVNEX2009] to the New Zealand Ministry of Health. Unpublished report to the Ministry of
Health.
® Hingston RW, Edwards EM, Heeran T, Rosenbloom D. 2009. Age of drinking onset and injuries, motor vehicle
crashes, and physical fights after drinking and not drinking. Alcoholism: Clinical and Experimental Research 33(5):
783–790.
® Hingson RW, Heeren T, Winter MR. 2006. Age at drinking onset and alcohol dependence: age at onset, duration, and
severity. Archives of Pediatrics & Adolescent Medicine 160(7): 739–46.
® Jay M. 1999. Why do people take drugs? International Journal of Drug Policy 10(2): 5–7.
® Jennison KM, Johnson KA. 1998. Alcohol dependence in adult children of alcoholics: longitudinal evidence of early
risk. Journal of Drug Education 28(1): 19–37.
® Komro KA, Tobler AL, Maldonado-Molina MM, Perry CL. 2010. Effects of alcohol use initiation patterns on high-risk
behaviors among urban, low-income, young adolescents. Prevention Science 11: 14–23.
® Lann MA, Molina DK. 2009. A fatal case of benzodiazepine withdrawal. American Journal of Forensic Medicine &
Pathology 30(2): 177–179.
® Livingston JD, Milne T, Fang ML, Amari E. 2012. The effectiveness of interventions for reducing stigma related to
substance use disorders. Addiction 107(1): 39–50.
® Mallard SR, Connor JL, Houghton LA. 2013. Maternal factors associated with heavy periconceptional alcohol intake
and drinking following pregnancy recognition: A post-partum survey of New Zealand women. Drug and Alcohol
Review 32(4): 389–397.
® Maynard S. 1997. Growing up in an alcoholic family system: the effect on anxiety and differentiation of self. Journal
of Substance Abuse 9: 161–170.
® Meier MH, Caspi A, Ambler A, et al. 2012. Persistent cannabis users show neuropsychological decline from childhood
to midlife. Proceedings of the National Academy of Sciences of the United States of America 109(40): 2657–2664.
® Mental Health Commission. 2011. National Indicators 2011: Measuring mental health and addiction in New Zealand.
URL: http://www.hdc.org.nz/media/199059/national%20indicators%202011%20measuring%20mental%20health%20
and%20addiction%20in%20new%20zealand.pdf
® Ministry of Education. 2013. Stand-downs, suspensions, exclusions and expulsions from school. Education Counts.
URL: www.educationcounts.govt.nz/indicators/main/student-engagement-participation/Stand-downs-suspensions-
exclusions-expulsions.
® Ministry of Health. 2009a. Alcohol Use in New Zealand: Key results of the 2007/08 New Zealand Alcohol and Drug
Use Survey. Wellington: Ministry of Health.
® Ministry of Health. 2009b. Research into Knowledge and Attitudes to Illegal Drugs. Wellington: Acumen Ltd & UMR
Ltd.
® Ministry of Health. 2010. Drug Use in New Zealand: Key results of the 2007/08 New Zealand Alcohol and Drug Use
Survey. Wellington: Ministry of Health.
® Ministry of Health. 2013a. Hazardous Drinking in 2011/2012: Findings from the New Zealand Health Survey. URL:
www. health.govt.nz/system/files/documents/publications/12-findings-from-the-new-zealand-health-survey.pdf
® Ministry of Health. 2013b. Health Loss in New Zealand: A report from the New Zealand Burden of Diseases, Injuries
and Risk Factors Study, 2006–2016. Wellington: Ministry of Health.
® Ministry of Health. 2014a. Tobacco Use 2012/13: New Zealand Health Survey. Wellington: Ministry of Health.
® Ministry of Health. 2014b. New Zealand Health Survey — Annual update of key findings 2013/2014: Adult data tables
— Health status, health behaviours and risk factors. Wellington: Ministry of Health.
® Ministry of Health. 2014c. Amphetamine Use 2013/14: New Zealand Health Survey. Wellington: Ministry of Health.
® Ministry of Health. 2014d. Unpublished data from National Collections PRIMHD datamart. Accessed September
2014.
® Ministry of Health. 2015a. Alcohol Use 2012/13: New Zealand Health Survey. Wellington: Ministry of Health.
® Ministry of Health. 2015b. Unpublished data from Drug Use 2012/13: New Zealand Health Survey.
® Ministry of Justice. 2010. The New Zealand Crime and Safety Survey: 2009. Wellington: Ministry of Justice.
® Ministry of Transport. 2014. Alcohol and drugs 2014. URL: http://www.transport. govt.nz/assets/Uploads/Research/
Documents/Alcohol-drugs-2014.pdf.
® Morton SMB, Atatoa Carr PE, Bandara DK, et al. 2010. Growing Up in New Zealand: A longitudinal study of New
Zealand children and their families. Report 1: Before we are born. Auckland: Growing Up in New Zealand.
® Noller G, Henderson C. 2014. Report of the National Needle Exchange Blood-borne Virus Seroprevalence Survey.
[BBVNEX2013] to the New Zealand Ministry of Health. Unpublished report to the Ministry of Health.
® Office of the Chief Coroner. 2012. Recommendations Recap: a summary of coronial recommendations and comments
made between 1 January–31 March 2012. Issue 2. New Zealand: Officer of the Chief Coroner.
® Office of the Prime Minister’s Science Advisory Committee, Gluckman PD. 2011. Improving the Transition: Reducing
social and psychological morbidity during adolescence. Wellington: Office of the Prime Minister’s Science Advisory
Committee.
® Peto, Lopez, et al. Mortality from Smoking in Developing Countries 1950–2010 (revised March 2012). URL:
www.ctsu. ox.ac.uk/research/mega-studies/mortality-from-smoking-in-developed-countries-1950–2010.
® Research New Zealand. 2014. HPA Attitudes and Behaviour Towards Alcohol Survey 2010–2012: Report 1.2 –
Planning, actions and consequences of the last drinking occasion (adults, 18 years and over). Wellington: Health
Promotion Agency.
® Robin Room, et al. 2008. The Global Cannabis Commission Report – Cannabis Policy: Moving Beyond Stalemate.
URL http://www.undrugcontrol.info/en/issues/cannabis/item/2406-cannabis-policy-moving-beyond-stalemate.
® Silins E, Horwood LJ, Patton GC, et al. 2014. Young adult sequelae of adolescent cannabis use: an integrative analysis.
Lancet Psychiatry 1: 286–93.
® Squeglia LM, Jacobus J, Tapert SF. 2009. The influence of substance use on adolescent brain development. Clinical
EEG and Neuroscience 40(1): 31–38.
® Swahn MH, Bossarte RM, Ashby JS, Meyers J. 2010. Pre-teen alcohol use initiation and suicide attempts among
middle and high school students: findings from the 2006 Georgia Student Health Survey. Addictive Behaviours. May;
35(5):452–8.
® The University of Auckland. 2014. Problem substance use among New Zealand secondary school students: Findings
from the Youth’12 National Youth Health and Wellbeing Survey. Auckland: The University of Auckland – Faculty of
Medical and Health Sciences.
® Wells JE, Baxter J, Schaaf D (eds). 2007. Substance Use Disorders in Te Rau Hinengaro: The New Zealand Mental
Health Survey. Wellington: Alcohol Advisory Council of New Zealand.
® Wilkins C, Sweetsur, P. 2012. Criminal justice outcomes for cannabis use offences in New Zealand, 1991–2008.
International Journal of Drug Policy 23(6): 505–511.
® Barker CA. 2011. Children in New Zealand methamphetamine laboratories. PhD thesis, ResearchSpace@Auckland,
University of Auckland.
® Business and Economic Research Limited (BERL). 2008. New Zealand Drug Harm Index. Wellington: BERL
Economics.
® Casas-Gill MJ, Navarro-Guzman JI. 2002. School characteristics among children of alcoholic parents. Psychological
Reports 90: 341–8.
® Child and Youth Mortality Review Committee, Te Rōpū Arotake Auau Mate o te Hunga Tamariki, Taiohi. 2013.
Special Report: Unintentional deaths from poisoning in young people. Wellington: Child and Youth Mortality Review
Committee.
® Darke S, Kaye S, McKetin R, et al. 2008. Major physical and psychological harms of methamphetamine use. Drug and
Alcohol Review 27: 253.
® Expert Advisory Committee on Drugs. 2004. Advice to the Minister on ,4-methylendioxymethamphetamine (MDMA).
URL: www.health.govt.nz/system/files/documents/pages/eacdmdma.pdf
® Fisk J, Murphy P, Montgomery C, et al. 2011. Modelling the adverse effects associated with ecstasy use. Addiction
106: 798–805.
® Hoaken P, Stewart S. 2003. Drug of abuse and the elicitation of human aggressive behaviour. Addictive Behaviour
28(9): 1533–54.
® Hyphantis T, Koutras V, Liakos A, et al. 1991. Alcohol and drug use, family situation and school performance in
adolescent children of alcoholics. International Journal of Social Psychiatry 37(1): 35–42.
® Krasnova IN, Cadet JL. 2009. Methamphetamine toxicity and messengers of death. Brain Research Reviews 60(2):
379, 380.
® Lynskey MT, Fergusson DM. 1994. The effect of parental alcohol problems on rates of adolescent psychiatric
disorders. Addiction 89(10): 1277–86.
® McKetin R, McLaren J, Riddell S, et al. 2006. The relationship between methamphetamine use and violent behaviour.
BOSCAR NSW Crime and Justice Bulletin 97.
® Ministry of Health. 2013. New Zealand Health Survey: Annual update of key findings 2012/2013. Wellington. Ministry
of Health.
® National Drug Intelligence Bureau. 2013. Illicit Drug Assessment. Wellington: National Drug Intelligence Bureau.
® New Zealand Law Commission. 2010. Controlling and Regulating Drugs: A review of the Misuse of Drugs Act 1975.
Issues Paper 16. Wellington: New Zealand Law Commission.
® Obot IS, Anthony JC. 2004. Mental health problems in adolescent children of alcohol dependent parents: epidemiologic
research with a nationally representative sample. Journal of Child and Adolescent Substance Abuse 13(4): 88–96.
® Room R, Fischer B, Lenton S, et al. 2008. The Global Cannabis Commission Report – Cannabis policy: Moving
beyond stalemate. Oxford: The Beckley Foundation.
® Todd FC. 2010. Te Ariari o te Oranga: The Assessment and Management of People with Co-existing Mental Health
and Substance Use Problems. Wellington: Ministry of Health.
® White J. 2013. Use of Alcohol Among Year 10 students. [In Fact]. Wellington: Health Promotion Agency Research and
Evaluation Unit.
® Wilkins C, Sweetsur P, Moewaka Barnes H, et al. 2012. New Zealand Drug Use Monitoring (NZ-ADUM) 2011 Report.
Auckland: SHORE and Whariki Research Centre, Massey University.
® Wilkins C, Sweetsur P, Smart B, et al. 2012. Recent Trends in Illegal Drug Use in New Zealand: Findings from the
2006, 2007, 2008, 2009, 2010 and 2011 Illicit Drug Monitoring System (IDMS). Auckland: SHORE and Whariki
Research Centre, Massey University.